Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Does the presence of a BRCA 1/2 mutation affect your recommendation for post-mastectomy RT in patients with pT1-2, N0 disease?
Answer from: Radiation Oncologist at Community Practice
It doesn’t influence RT decision.
Sign In
or
Register
to read more
11230
Related Questions
Would you consider APBI in a patient who meets all criteria but has high-risk genomic testing and is not receiving chemotherapy?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
Would you recommend post mastectomy radiation for a low grade adenoid cystic carcinoma of the breast resected with negative margins?
How would you treat a schwannoma of the breast with a positive margin that is not amenable to re-excision?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
How, if at all, does your practice differ between male and female breast cancer patients with respect to the use of bolus?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?